Premium
A synbiotic marine oligosaccharide microcapsules for enhancing Bifidobacterium longum survivability and regulatory on intestinal probiotics
Author(s) -
Chang Liuyi,
Wang Peng,
Sun Shujuan,
Shen Zhaopeng,
Jiang Xiaolu
Publication year - 2021
Publication title -
international journal of food science and technology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.831
H-Index - 96
eISSN - 1365-2621
pISSN - 0950-5423
DOI - 10.1111/ijfs.14650
Subject(s) - bifidobacterium longum , oligosaccharide , probiotic , bifidobacterium , food science , microbiology and biotechnology , bifidobacterium breve , chemistry , prebiotic , in vivo , in vitro , synbiotics , lactobacillus , biology , bacteria , biochemistry , fermentation , genetics
Summary A novel synbiotic multiparticulate microparticle containing alginate oligosaccharide (AOS), chitosan oligosaccharide (COS) and Bifidobacterium longum CICC 6259 was produced in the current study to expand the synbiotic industrial applications. The influences of these treatments on encapsulation yield, size, morphology, protective effect and stability of microcapsules and on mice gut microbiome were studied in vitro and in vivo . In vitro experiments detected no significant difference ( P > 0.05) in encapsulation yield with different types of microcapsules. However, the microcapsule diameter of marine oligosaccharide was approximately 60 μm greater, and these microcapsules increased the number of surviving cells by more than 3 log cfu/g after treatment with simulated gastrointestinal juices, compared to basic alginate microcapsules. In vivo , these microcapsules significantly increased the content of Bifidobacterium and Lactobacillus and reduced the content of Enterococcus and Escherichia in mice gut microbiome. Marine oligosaccharide probiotic microcapsules are promising as a novel functional food ingredient.